Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age
NEW YORK and MAINZ, GERMANY, APRIL 26, 2022— Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10-µg...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Children | Clinical Trials | Covid Vaccine | COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Germany Health | Pfizer | Pharmaceuticals | Vaccines